Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of Schistosoma mansoni.

IF 3.8 2区医学 Q2 CHEMISTRY, MEDICINAL

ACS Infectious Diseases Pub Date : 2025-07-02 DOI:10.1021/acsinfecdis.5c00224

Emanuele Fabbrizi, Gebremedhin Solomon Hailu, A Ganesan, Rossella Fioravanti, Clemens Zwergel, Chiara Lambona, Sergio Valente, Giulia Fianco, Angela Iuzzolino, Daniela Trisciuoglio, Jonatan Caroli, Andrea Mattevi, Cécile Häberli, Jennifer Keiser, Dante Rotili, Antonello Mai

引用次数: 0

Abstract

Schistosoma infections remain a major public health issue mainly in tropical and subtropical regions. While Praziquantel is the primary treatment for schistosomiasis, its limitations include resistance development and poor efficacy against juvenile worms. Given the biological similarities between tumor and parasite-infected cells, LSD1 inhibitors─primarily explored as anticancer agents─have been investigated for their antiparasitic potential.

查看原文本刊更多论文

基于tranylcylers的LSD1抑制剂作为降低曼氏血吸虫活力的有效药物。

血吸虫感染仍然是一个主要的公共卫生问题，主要发生在热带和亚热带地区。虽然吡喹酮是血吸虫病的主要治疗方法，但其局限性包括产生耐药性和对幼虫的疗效较差。鉴于肿瘤和寄生虫感染细胞之间的生物学相似性，LSD1抑制剂（主要是作为抗癌药物探索的）的抗寄生虫潜力已经得到了研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES

CiteScore

9.70

自引率

3.80%

发文量

213

期刊介绍： ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.